June 2014 Tucson pulmonary journal club: pirfenidone in idiopathic pulmonary fibrosis

• Main Authors: Alzoubaidi M, Knox KS
• Format: Article
• Language: English
• Published: Arizona Thoracic Society 2014-10-01
• Series: Southwest Journal of Pulmonary and Critical Care
• Subjects: pirfenidone; IPF; idiopathic pulmonary fibrosis; cryptogenic fibrosiing alveolitis; clinical trial; forced vital capacity; randomized; double-blind; efficacy; antifibrotic
• Online Access: http://www.swjpcc.com/pulmonary-journal-club/2014/10/29/june-2014-tucson-pulmonary-journal-club-pirfenidone-in-idiop.html

No abstract available. Article truncated at 150 words. Idiopathic pulmonary fibrosis is a chronic, progressive, and fatal lung disease that is characterized by irreversible loss of lung function. The 5-year survival rate that is similar to the rates for several cancers (1). In the 2011, the official ATS/ERS/JRS/ALAT statement regarding idiopathic pulmonary fibrosis underlined that the preponderance of evidence to date suggests that pharmacologic therapy for IPF is without definitive, proven benefit (2). The committee made recommendations of varying strength against most therapies. Pirfenidone is a pyridone compound with anti-inflammatory, antifibrotic, and antioxidant properties, with antagonism of Transforming Growth Factor (TGF)- B1 effects. Pirfenidone inhibits fibroblast proliferation and collagen synthesis and reduce cellular and histological markers of fibrosis in animal models of lung fibrosis. Three previous phase 3 randomized, double-blind, placebo-controlled, that examined pirfenidone for idiopathic pulmonary fibrosis had varying results (3,4). That led to the approval of pirfenidone for idiopathic pulmonary fibrosis by many governing bodies worldwide ...